Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[68Ga]-Pentixafor-PET Imaging in Hematologic and Solid Tumors
NCT05093335Phase 1Recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Oct 2021
- Primary completion
- Oct 2027
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of pentixafor in non-Hodgkin lymphoma (NHL), multiple myeloma (MM), Histiocytic Neoplasm (HN) and 3 more, sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Tumor standard uptake value at 1 year. Started Oct 2021; status: recruiting.
02
Drugs
pentixafor
03
Conditions
non-Hodgkin lymphoma (NHL)multiple myeloma (MM)Histiocytic Neoplasm (HN)Erdheim-Chester disease (ECD)Rosai-Dorfman disease (RDD)
Beyond the preview
Go deeper on NCT05093335.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05093335.